enGene Stock (NASDAQ:ENGN)
Previous Close
$7.91
52W Range
$2.65 - $9.65
50D Avg
$6.69
200D Avg
$5.08
Market Cap
$375.24M
Avg Vol (3M)
$267.20K
Beta
-0.26
Div Yield
-
ENGN Company Profile
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.